Micro-elimination of Hepatitis C Virus Infection in Uremics
Status:
Active, not recruiting
Trial end date:
2024-04-15
Target enrollment:
Participant gender:
Summary
There is a huge gap between the clinical efficacy and community effectiveness in the
treatment of chronic hepatitis C in Taiwan. HCV infection prevails in uremic patients with
the prevalence of > 10 % in Taiwan.The current study will be executed in each participating
hemodialysis centers by an outreach team of HCV treaters, treating all of the HCV-viremic
uremia patients and HD staffs at the same time (group therapy) in each individual HD center
(Erase-C campaign) with all oral directly-acting antivirals, to ensure the rates of
diagnosis, accessibility, treatment and follow-up.The purpose of the study is to demonstrate
a model of care using outreach HCV treaters by implementing the concept of "group therapy"
with one-size-fit-all pangenotypic DAA regimen, 12 weeks of sofosbuvir/velpatasvir, in each
individual hemodialysis center (Erase-C campaign) to achieve HCV micro-elimination.
Phase:
Phase 3
Details
Lead Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital